Navigation Links
Transgenomic and Power3 Medical Report Identification of Abnormal Serum Proteins in Parkinson's Disease
Date:9/2/2009

OMAHA, Neb. and HOUSTON, Sept. 2 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO) and Power3 Medical Products, Inc. (OTC Bulletin Board: PWRM) today announced the advance on-line publication of a clinical research paper entitled "Abnormal Serum Concentrations of Proteins in Parkinson's Disease" in the scientific journal Biochemical and Biophysical Research Communications. The study demonstrates the usefulness of a protein biomarker panel to distinguish Parkinson's disease (PD) patients from age-matched normal controls independent of the severity of symptoms, using clinical blood serum samples.

The analytic technology forms the basis for the NuroPro(R)PD test for PD being commercialized by Transgenomic as per a licensing/collaboration agreement with Power3 Medical signed in early 2009. The publication of the peer-reviewed article is a significant validation milestone in the ongoing clinical development of the NuroProPD diagnostic assay.

The article describes the use of analytically validated quantitative 2D gel electrophoresis to identify protein biomarkers for diagnosing PD using serum from routinely collected blood samples. 57 protein biomarkers, which had been discovered using retrospective blood serum samples from various neurodegenerative diseases, were then applied specifically to PD in a prospective clinical investigation using freshly collected blood serum from PD patients and age-matched normal controls. A multi-variate statistical method, stepwise linear discriminant analysis, selected a combination of 21 of the biomarkers as optimal to distinguish PD patients from controls. When applied to the PD samples, the 21-protein set had sensitivity of 93.3% (52 of 56 PD correctly classified) and specificity of 92.9% (28 of 30 controls correctly classified); 15 of 15 patients with mild and 28 of 30 with moderate to severe symptoms were correctly classif
'/>"/>

SOURCE Transgenomic, Inc.; Power3 Medical Products, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Transgenomic, Inc. Reports Second Quarter 2009 Results
2. Reminder: Transgenomic Inc. Announces Second Quarter 2009 Earnings Release Conference Call Webcast
3. Webcast Alert: Transgenomic Inc. Announces Second Quarter 2009 Earnings Release Conference Call Webcast
4. Transgenomic, Inc. Announces Appointment of New Board Members
5. Transgenomic, Inc. Reports First Quarter 2009 Results
6. Reminder: Transgenomic Inc. Announces First Quarter 2009 Earnings Release Conference Call Webcast
7. Transgenomic and Power3 Medical Introduce NuroPro(R) Tests for Alzheimers and Parkinsons Diseases at AAN Annual Meeting
8. Webcast Alert: Transgenomic Inc. Announces First Quarter 2009 Earnings Release Conference Call Webcast
9. Transgenomic Completes Licensing Option With Dana-Farber Cancer Institute on Cold-PCR for Enrichment of DNA Mutations
10. Polycystic Kidney Disease Assay at Cornell University Uses Transgenomics Surveyor Nuclease & WAVE Technology
11. Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... (PRWEB) July 30, 2014 Yuma ... facility and complementary therapies brings comprehensive cancer care ... state-of-the-art Yuma Regional Cancer Center has officially opened. ... the program includes services such as open, semi-private ... therapy, American Cancer Society Resource Center, hematology, rehabilitation ...
(Date:7/30/2014)... JUPITER, Fla. , July 30, 2014 /PRNewswire/ ... global biotechnology company whose patented and proprietary technologies ... enzymes and other proteins for the bioenergy, bio-based ... the appointment of Thomas "Tom" Dubinski as Vice ... responsible for leading the financial and information technology ...
(Date:7/30/2014)... 2014   Epic Sciences, Inc. ("Epic"), a ... to personalize and advance the treatment and management of ... Lucier as chairman of Epic,s board of directors. ... Technologies (formerly Invitrogen). Mr. Lucier joins Epic,s board of ... rare cell analysis platform with special focus on the ...
(Date:7/30/2014)... 30, 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... focused on discovering, developing and commercializing innovative ... RNA-targeted technologies, today announced that their third ... the reduction of recurrence of hypertrophic scars ... initiated. Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
Breaking Biology Technology:Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5
... Informed Medical Communications (IMC), a leading provider ... today announced the appointment of Kerry Crawford to ... In this critical role, Kerry will lead operations ... client relationship management systems. This key addition ...
... Collexis Holdings Inc.,(OTC Bulletin Board: CLXS), a ... announced today the launch of the world,s first,CTSA ... 38 institutions and,their more than 60,000 life science ... are also winners of the Clinical Translational Science,Awards ...
... Denmark, March 3 Following the,completion of the Phase ... Nordic has held an end of Phase,II meeting with ... meeting was,a success and there was an open and ... This meeting represented the first ever formal discussions ...
Cached Biology Technology:Informed Medical Communications Appoints New Senior Manager, Strategic Operations 2Collexis Connects the NIH Clinical and Translational Science Award Programs with CTSA Expert Platform 2Collexis Connects the NIH Clinical and Translational Science Award Programs with CTSA Expert Platform 3Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting 2Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting 3
(Date:7/30/2014)... of researchers from the University of Helsinki and the ... reproduce in mice morphological changes which have taken millions ... in the embryonic development of mice teeth, induced in ... very similar to those observed in the fossil registry ... years ago. , To modify the development of ...
(Date:7/30/2014)... of $1 million from the Cornelia Cogswell Rossi Foundation ... Center. , The newly established Connie Cogswell ... develop a greater breadth and depth of knowledge of ... pace of research to improve human health. , The ... the Laboratory and its external partners, supporting research to ...
(Date:7/30/2014)... , July 30, 2014 ... mitigation and liveness detection solutions for the biometric ... an industry consortium revolutionizing online authentication with standards ... Mark Cornett , "The decision to join FIDO ... biometric authentication pervasive in use. We believe the ...
Breaking Biology News(10 mins):Scientists reproduce evolutionary changes by manipulating embryonic development of mice 2Rossi Foundation pledges $1M for JAX neurobehavioral research center 2NexID Biometrics Joins the FIDO Alliance 2
... of us never considered eating the mud pies we made ... dining on dirt is nothing out of the ordinary. Now ... The Quarterly Review of Biology helps explain why. ... human geophagythe eating of earthis that it protects the stomach ...
... a researcher, please contact the Communications and External Relations staff member ... ORNL and its research and development activities, please refer to one ... or comment, you can send it to news@ornl.gov . ... Unsafe commercial motor vehicles may be off the ...
... like a computer. An organism,s genome is the software ... do. But instead of electronic circuitry, life relies on ... organisms to function. Now, researchers at the California Institute ... circuit ever created from scratch, made with DNA-based devices ...
Cached Biology News:Eating dirt can be good for the belly, researchers find 2Eating dirt can be good for the belly, researchers find 3Story tips from the Department of Energy's Oak Ridge National Laboratory, June 2011 2Caltech researchers build largest biochemical circuit out of small synthetic DNA molecules 2Caltech researchers build largest biochemical circuit out of small synthetic DNA molecules 3Caltech researchers build largest biochemical circuit out of small synthetic DNA molecules 4
... 3′-(α-Amino- p- methoxyhydrocinnamamido)-3′-deoxy-N,N-dimethyladenosine, 2HCl ... MOISTURE. Protein synthesis inhibitor. Inhibits translation ... polypeptide chains. Induces DNA fragmentation in ... cells. Purity: ≥98% by TLC. ...
... Stabilizer is a bovine protein-free alternative ... is an aqueous solution that contains ... buffer (3-(N-Morpholino) propanesulfonic acid), pH 6.0 ... of 0.02% methylisothiazolone and 0.02% bromonitrodioxane ...
... quantitation kit is used to quantitate double-stranded DNA ... RNA or protein. With this kit, DNA is ... detected with a VersaFluor or other fluorometer. The ... ng per ml to 5 micrograms per ml ...
... Reagent A: MTT, (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide), 50mg/vial. ... is cleaved by living cells to yield ... requires active mitochondria, and even freshly dead ... MTT. Reagent A is a component of ...
Biology Products: